Subscribe To

Price Alert Latest News Economic Calendar News

VYNT / Vyant Bio Shares Jump On Parkinson's Disease Agreement

Vyant Bio Inc (NASDAQ: VYNT) and OrganoTherapeutics have entered into a collaboration agreement to work toward accelerating the discovery of drugs for the treatment of Parkinson's Disease. Specific deal terms were not disclosed. Read More

Demo Live Account See Partner Details

Content Topics

Vyant

Jump

Parkinson

Disease

Agreement

Parkinson s

Stock

VYNT

Posted: Mar 30 2022, 06:25

Author Name: Benzinga

VYNT News

By Proactive Investors
May 12, 2023

Vyant Bio to pursue listing on OTC Pink Open Market

Vyant Bio (NASDAQ:VYNT) said its last day of trading on the Nasdaq Capital Market will be May 12, 2023. following its filing to voluntarily delist

By Proactive Investors
February 3, 2023

Vyant Bio commences cash conservation plan including ‘reduction in force' as it continues to explore strategic alternatives

Vyant Bio (NASDAQ:VYNT) has told investors that the company's president and CEO John Roberts and chief scientific officer Dr Robert Fremeau have agree

By Proactive Investors
January 4, 2023

Vyant Bio appoints LifeSci Capital to review strategy focused on enhancing shareholder value

Vyant Bio (NASDAQ:VYNT) Inc has engaged LifeSci Capital as its financial advisor to assist in exploring a range of strategic alternatives focused on

By Seeking Alpha
November 17, 2022

Vyant Bio, Inc. (VYNT) Q3 2022 Earnings Call Transcript

Vyant Bio, Inc. (NASDAQ:VYNT ) Q3 2022 Earnings Conference Call November 16, 2022 4:30 PM ET Company Participants Jay Roberts - Chief Executive Office

By Proactive Investors
November 15, 2022

Vyant Bio in position to be fully funded through 2023 following sale of subsidiary, 3Q results show

Vyant Bio (NASDAQ:VYNT) Inc has reported its third-quarter financial results and announced it expects to be able to fund operations through to at leas

By Proactive Investors
November 3, 2022

Vyant Bio sells biotech branch vivoPharm to Reaction Biology for $5.5 million

Vyant Bio (NASDAQ:VYNT) Inc said it has closed a definitive agreement with Reaction Biology Corporation in the sale of its subsidiary vivoPharm LLC, a

By Proactive Investors
August 23, 2022

Vyant Bio posts Q2 results, set to advance VYNT-0126 to treat Rett Syndrome into clinical trials early next year

Vyant Bio (NASDAQ:VYNT) Inc revealed that it is advancing its repurposed drug candidate, VYNT-0126 to treat Rett Syndrome, into clinical trials early

By Seeking Alpha
August 22, 2022

Vyant Bio, Inc. (VYNT) CEO Jay Roberts on Q2 2022 Results - Earnings Call Transcript

Vyant Bio, Inc. (NASDAQ:VYNT ) Q2 2022 Results Earnings Conference Call August 22, 2022 4:30 PM ET Company Participants Jay Roberts - President and Ch

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.